Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Recruiting Phase 3 Interventional Study
Smoking Cessation
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
500 (estimated)
Sponsor
University of Kansas Medical Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * African American * age \>18 years * interested in quitting * smoked \>1 cpd for \>1 years * smoked on \>25 days in the past month * willing to take 6 months of study medication and complete all visits * have a home address and functioning telephone number Exclusion Criteria: …
Contacts

Tricia Snow, MPH

816-398-8960

psnow@kumc.edu

CONTACT